They also revealed that under the treatment of EGFR TKIs, adenocarcinomas with TTF-1+ and EGFR mutation had a better outcome and in EGFR-mutated patients, those with TTF-1− adenocarcinoma had worse PFS than what those with TTF-1+ adenocarcinoma did [13]. This evidence concerns the gene TTF1 and adenocarcinoma.